Carolina Schinke
Concepts (299)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 64 | 2024 | 3035 | 6.880 |
Why?
| Antibodies, Bispecific | 4 | 2024 | 43 | 1.550 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 34 | 1.440 |
Why?
| Bone Marrow | 11 | 2024 | 411 | 1.440 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 39 | 1.390 |
Why?
| Paraproteinemias | 2 | 2022 | 80 | 1.370 |
Why?
| Neoplasm, Residual | 6 | 2022 | 166 | 1.220 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 108 | 1.180 |
Why?
| Hematopoietic Stem Cell Transplantation | 5 | 2024 | 573 | 1.130 |
Why?
| Immunoglobulin Light Chains | 2 | 2017 | 101 | 1.100 |
Why?
| Humans | 78 | 2024 | 54284 | 0.970 |
Why?
| Myelodysplastic Syndromes | 5 | 2016 | 79 | 0.970 |
Why?
| Immunoconjugates | 2 | 2022 | 38 | 0.950 |
Why?
| Mutation | 8 | 2022 | 1501 | 0.880 |
Why?
| Leukemia, Myeloid, Acute | 4 | 2019 | 191 | 0.840 |
Why?
| Antibodies, Monoclonal | 6 | 2023 | 562 | 0.810 |
Why?
| Gene Expression Profiling | 10 | 2023 | 1138 | 0.760 |
Why?
| Testis | 1 | 2021 | 65 | 0.760 |
Why?
| Prognosis | 15 | 2024 | 2118 | 0.750 |
Why?
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 866 | 0.740 |
Why?
| Hematopoietic Stem Cells | 3 | 2019 | 215 | 0.710 |
Why?
| B-Cell Maturation Antigen | 6 | 2024 | 72 | 0.690 |
Why?
| Clonal Evolution | 4 | 2024 | 60 | 0.680 |
Why?
| Cell Proliferation | 8 | 2023 | 1096 | 0.670 |
Why?
| Gene Expression | 3 | 2018 | 664 | 0.650 |
Why?
| Clinical Trials as Topic | 6 | 2023 | 490 | 0.600 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1056 | 0.590 |
Why?
| Translocation, Genetic | 5 | 2021 | 287 | 0.580 |
Why?
| Thoracic Neoplasms | 1 | 2016 | 11 | 0.560 |
Why?
| Plasmacytoma | 1 | 2016 | 47 | 0.540 |
Why?
| Receptors, Interleukin-8B | 1 | 2015 | 4 | 0.530 |
Why?
| Interleukin-8 | 1 | 2015 | 97 | 0.510 |
Why?
| Aged | 19 | 2023 | 10054 | 0.500 |
Why?
| Plasma Cells | 5 | 2023 | 238 | 0.470 |
Why?
| Survival Analysis | 7 | 2021 | 735 | 0.450 |
Why?
| Antineoplastic Agents | 7 | 2024 | 1300 | 0.440 |
Why?
| Combined Modality Therapy | 4 | 2024 | 692 | 0.430 |
Why?
| Signal Transduction | 4 | 2021 | 1753 | 0.430 |
Why?
| Fluorodeoxyglucose F18 | 5 | 2021 | 205 | 0.420 |
Why?
| Neutropenia | 2 | 2023 | 120 | 0.420 |
Why?
| DNA Methylation | 4 | 2020 | 574 | 0.420 |
Why?
| Male | 24 | 2021 | 27334 | 0.410 |
Why?
| Oncogene Proteins, Fusion | 2 | 2018 | 60 | 0.410 |
Why?
| Transplantation, Autologous | 6 | 2024 | 476 | 0.400 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 50 | 0.390 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2023 | 113 | 0.390 |
Why?
| Middle Aged | 18 | 2021 | 13088 | 0.390 |
Why?
| Epigenesis, Genetic | 4 | 2020 | 399 | 0.380 |
Why?
| Stem Cell Transplantation | 3 | 2022 | 196 | 0.380 |
Why?
| Positron-Emission Tomography | 4 | 2022 | 322 | 0.380 |
Why?
| Evolution, Molecular | 2 | 2021 | 103 | 0.380 |
Why?
| Adult | 15 | 2022 | 14207 | 0.370 |
Why?
| Tretinoin | 1 | 2010 | 56 | 0.360 |
Why?
| Neoplasm Recurrence, Local | 6 | 2024 | 644 | 0.350 |
Why?
| Immunoglobulin kappa-Chains | 2 | 2021 | 31 | 0.340 |
Why?
| Transcription Factors | 3 | 2023 | 622 | 0.330 |
Why?
| Aged, 80 and over | 7 | 2021 | 3431 | 0.310 |
Why?
| Tumor Microenvironment | 3 | 2023 | 209 | 0.300 |
Why?
| DNA-Binding Proteins | 2 | 2021 | 462 | 0.300 |
Why?
| Neoplasm Proteins | 3 | 2020 | 359 | 0.300 |
Why?
| Melanoma | 1 | 2010 | 313 | 0.290 |
Why?
| Transcriptome | 2 | 2020 | 346 | 0.290 |
Why?
| Female | 21 | 2021 | 28441 | 0.280 |
Why?
| Treatment Outcome | 8 | 2022 | 5604 | 0.280 |
Why?
| Disease Progression | 7 | 2023 | 913 | 0.270 |
Why?
| Biopsy | 2 | 2018 | 692 | 0.260 |
Why?
| Radiopharmaceuticals | 3 | 2021 | 238 | 0.250 |
Why?
| Cell Line, Tumor | 5 | 2023 | 1550 | 0.250 |
Why?
| Dexamethasone | 3 | 2024 | 435 | 0.250 |
Why?
| Skin Neoplasms | 1 | 2010 | 532 | 0.250 |
Why?
| Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.250 |
Why?
| Kaplan-Meier Estimate | 3 | 2021 | 514 | 0.240 |
Why?
| T-Lymphocytes | 5 | 2024 | 373 | 0.240 |
Why?
| Mutation Rate | 2 | 2021 | 40 | 0.240 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 55 | 0.240 |
Why?
| Myeloproliferative Disorders | 1 | 2023 | 28 | 0.230 |
Why?
| Cell Cycle | 2 | 2021 | 275 | 0.220 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 90 | 0.210 |
Why?
| Genomics | 2 | 2023 | 310 | 0.210 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.210 |
Why?
| Osteolysis | 1 | 2022 | 88 | 0.210 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 41 | 0.210 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 62 | 0.200 |
Why?
| Hematologic Diseases | 1 | 2021 | 25 | 0.200 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 149 | 0.200 |
Why?
| Patient Participation | 1 | 2022 | 70 | 0.200 |
Why?
| Abnormal Karyotype | 1 | 2021 | 6 | 0.200 |
Why?
| Chromosome Deletion | 2 | 2023 | 150 | 0.200 |
Why?
| Myeloma Proteins | 1 | 2021 | 26 | 0.200 |
Why?
| Immunoglobulin A | 1 | 2021 | 54 | 0.190 |
Why?
| Drug Design | 2 | 2013 | 133 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 126 | 0.190 |
Why?
| Communicable Diseases | 1 | 2021 | 58 | 0.190 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 36 | 0.190 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 240 | 0.190 |
Why?
| Hematologic Neoplasms | 1 | 2022 | 99 | 0.190 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 85 | 0.190 |
Why?
| Salvage Therapy | 1 | 2021 | 145 | 0.190 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| Immunoglobulin G | 1 | 2021 | 226 | 0.180 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 492 | 0.180 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 295 | 0.180 |
Why?
| Bone Resorption | 1 | 2022 | 326 | 0.180 |
Why?
| Gene Amplification | 1 | 2019 | 57 | 0.180 |
Why?
| Chromosomal Instability | 1 | 2019 | 17 | 0.180 |
Why?
| Bone Diseases | 1 | 2021 | 109 | 0.180 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 10 | 0.180 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 124 | 0.180 |
Why?
| Atrial Fibrillation | 1 | 2022 | 197 | 0.170 |
Why?
| Neoplasms, Second Primary | 1 | 2019 | 77 | 0.170 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 11 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 271 | 0.170 |
Why?
| Comorbidity | 1 | 2021 | 663 | 0.170 |
Why?
| Risk Assessment | 3 | 2019 | 1361 | 0.160 |
Why?
| Sulfonamides | 1 | 2019 | 146 | 0.160 |
Why?
| Spleen | 1 | 2019 | 186 | 0.160 |
Why?
| Models, Statistical | 1 | 2020 | 259 | 0.160 |
Why?
| Spinal Fractures | 1 | 2018 | 41 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 24 | 0.160 |
Why?
| Immunotherapy, Adoptive | 3 | 2024 | 134 | 0.160 |
Why?
| Risk Factors | 7 | 2021 | 3935 | 0.160 |
Why?
| Bacteremia | 1 | 2019 | 101 | 0.160 |
Why?
| Adipocytes | 1 | 2018 | 129 | 0.160 |
Why?
| Gene Rearrangement | 1 | 2018 | 76 | 0.150 |
Why?
| Kidney Function Tests | 1 | 2017 | 59 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 18 | 0.150 |
Why?
| Cell Differentiation | 3 | 2022 | 720 | 0.150 |
Why?
| Disease-Free Survival | 4 | 2019 | 485 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 43 | 0.150 |
Why?
| Calcification, Physiologic | 1 | 2017 | 42 | 0.150 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 138 | 0.150 |
Why?
| Histoplasma | 1 | 2016 | 29 | 0.150 |
Why?
| Pelvis | 1 | 2017 | 76 | 0.150 |
Why?
| Survival Rate | 4 | 2020 | 951 | 0.150 |
Why?
| CA-125 Antigen | 1 | 2016 | 20 | 0.140 |
Why?
| Chromosome Aberrations | 2 | 2023 | 316 | 0.140 |
Why?
| Receptor, TIE-2 | 1 | 2016 | 18 | 0.140 |
Why?
| HIV Infections | 1 | 2021 | 394 | 0.140 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.140 |
Why?
| Urea | 1 | 2016 | 83 | 0.140 |
Why?
| Histoplasmosis | 1 | 2016 | 53 | 0.140 |
Why?
| Indazoles | 1 | 2016 | 55 | 0.140 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 99 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 206 | 0.130 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 126 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 250 | 0.130 |
Why?
| Mice | 4 | 2024 | 6413 | 0.130 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 110 | 0.130 |
Why?
| Cell Cycle Checkpoints | 1 | 2015 | 35 | 0.130 |
Why?
| Immunologic Factors | 1 | 2016 | 130 | 0.130 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2015 | 219 | 0.120 |
Why?
| Cluster Analysis | 1 | 2015 | 249 | 0.120 |
Why?
| Thrombopoiesis | 1 | 2014 | 8 | 0.120 |
Why?
| Hydrazines | 1 | 2014 | 16 | 0.120 |
Why?
| Recurrence | 4 | 2021 | 690 | 0.120 |
Why?
| Benzoates | 1 | 2014 | 22 | 0.120 |
Why?
| Myocardium | 1 | 2017 | 441 | 0.120 |
Why?
| Time Factors | 2 | 2021 | 3213 | 0.120 |
Why?
| Neoplastic Stem Cells | 1 | 2015 | 103 | 0.120 |
Why?
| Kidney Diseases | 1 | 2017 | 293 | 0.120 |
Why?
| Immunotherapy | 1 | 2016 | 263 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 21 | 0.120 |
Why?
| Animals | 6 | 2024 | 14385 | 0.110 |
Why?
| Pyrazoles | 1 | 2014 | 110 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1693 | 0.110 |
Why?
| Cell Survival | 1 | 2015 | 657 | 0.110 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2012 | 30 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2016 | 1639 | 0.110 |
Why?
| Clone Cells | 2 | 2023 | 89 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 87 | 0.110 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 476 | 0.100 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 200 | 0.100 |
Why?
| Thalidomide | 1 | 2014 | 397 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2024 | 2387 | 0.100 |
Why?
| Flow Cytometry | 2 | 2012 | 546 | 0.100 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2010 | 10 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 278 | 0.090 |
Why?
| Response Elements | 1 | 2010 | 32 | 0.090 |
Why?
| Luciferases | 1 | 2010 | 57 | 0.090 |
Why?
| Gene Silencing | 1 | 2010 | 129 | 0.090 |
Why?
| Alleles | 2 | 2021 | 277 | 0.090 |
Why?
| Tumor Burden | 2 | 2020 | 142 | 0.090 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 206 | 0.090 |
Why?
| Transfection | 1 | 2010 | 399 | 0.090 |
Why?
| Molecular Structure | 1 | 2010 | 319 | 0.090 |
Why?
| Retrospective Studies | 4 | 2024 | 6432 | 0.090 |
Why?
| Histones | 2 | 2021 | 335 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 114 | 0.080 |
Why?
| Apoptosis | 2 | 2014 | 1300 | 0.080 |
Why?
| Syndecan-1 | 2 | 2021 | 82 | 0.080 |
Why?
| Remission Induction | 2 | 2021 | 221 | 0.080 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 477 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 171 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2010 | 1062 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 2100 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 82 | 0.060 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 50 | 0.060 |
Why?
| Demography | 1 | 2023 | 99 | 0.060 |
Why?
| Antibodies | 1 | 2024 | 178 | 0.060 |
Why?
| Cell Communication | 1 | 2023 | 72 | 0.060 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| Neoplasms | 1 | 2013 | 1316 | 0.050 |
Why?
| Patients | 1 | 2022 | 53 | 0.050 |
Why?
| Geography | 1 | 2022 | 81 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 40 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 97 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 63 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 286 | 0.050 |
Why?
| United States | 2 | 2023 | 5217 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 269 | 0.050 |
Why?
| Infant | 1 | 2010 | 3817 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 14 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 134 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1213 | 0.050 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 156 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 23 | 0.050 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 20 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 196 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 105 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 60 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 70 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 216 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 131 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2020 | 171 | 0.050 |
Why?
| Health Status Disparities | 1 | 2022 | 219 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 217 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 469 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 253 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 643 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 206 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 36 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 231 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 19 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 252 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 596 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 520 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 101 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 68 | 0.040 |
Why?
| Bone and Bones | 1 | 2021 | 516 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 684 | 0.040 |
Why?
| beta-Glucans | 1 | 2016 | 26 | 0.040 |
Why?
| Itraconazole | 1 | 2016 | 45 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 99 | 0.040 |
Why?
| Genes, ras | 1 | 2016 | 48 | 0.040 |
Why?
| Angiopoietin-1 | 1 | 2016 | 18 | 0.040 |
Why?
| Genes, p53 | 1 | 2016 | 60 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 767 | 0.040 |
Why?
| Amphotericin B | 1 | 2016 | 122 | 0.040 |
Why?
| Intestinal Obstruction | 1 | 2016 | 37 | 0.040 |
Why?
| Glycolysis | 1 | 2016 | 73 | 0.040 |
Why?
| Ileum | 1 | 2016 | 102 | 0.040 |
Why?
| Colonoscopy | 1 | 2016 | 105 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 335 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2016 | 125 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 95 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 142 | 0.030 |
Why?
| Fever | 1 | 2016 | 129 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 209 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 119 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 153 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 300 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 995 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 431 | 0.030 |
Why?
| Heart | 1 | 2017 | 360 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 392 | 0.030 |
Why?
| Megakaryocyte Progenitor Cells | 1 | 2014 | 1 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 697 | 0.030 |
Why?
| Weight Loss | 1 | 2016 | 271 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 746 | 0.030 |
Why?
| Antifungal Agents | 1 | 2016 | 363 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 10 | 0.030 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 39 | 0.030 |
Why?
| Early Diagnosis | 1 | 2013 | 96 | 0.030 |
Why?
| Azacitidine | 1 | 2012 | 37 | 0.030 |
Why?
| Karyotyping | 1 | 2012 | 92 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2012 | 65 | 0.030 |
Why?
| Cell Lineage | 1 | 2012 | 93 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2013 | 531 | 0.020 |
Why?
| Antigens, CD | 1 | 2012 | 242 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 446 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1604 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2013 | 806 | 0.020 |
Why?
| Cytokines | 1 | 2013 | 676 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1304 | 0.020 |
Why?
| Case-Control Studies | 1 | 2012 | 1228 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1543 | 0.020 |
Why?
|
|
Schinke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|